Payment overview · 2025
General Payments
$1,104.35
51 reported records · 21 companies
Healthcare provider profile · identity verified
Steven R Garner, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DUBLIN, GA · NPI 1477546281
Verified facts
What the public records show
CMS Open Payments records show Steven R Garner, M.D. received $1,104.35 in general payments during 2025 across 51 reported records.
GlaxoSmithKline, LLC. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $191.15 | 17.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.91 | 13.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.77 | 7.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.05 | 7.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.60 | 7.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.70 | 6.0% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $54.49 | 4.9% | 2 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $52.45 | 4.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.73 | 4.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.17 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.37 | 2.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.37 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.15 | 2.7% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $26.97 | 2.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $26.60 | 2.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $25.55 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.86 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.95 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.35 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.33 | 1.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $13.83 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,104.35 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $190.77 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $153.91 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $109.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.77 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.60 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.61 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $66.61 | 3 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $54.49 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $52.45 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.73 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $30.15 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $0.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 128 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
128 | 97 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
200 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 598 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 577 | 124 |
| Gabapentin | Gabapentin | 493 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 425 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 401 | 97 |
| Losartan Potassium | Losartan Potassium | 345 | 90 |
| Metformin Hcl | Metformin Hcl | 341 | 83 |
| Lisinopril | Lisinopril | 305 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 286 | 67 |
| Atenolol | Atenolol | 273 | 70 |
| Tramadol Hcl | Tramadol Hcl | 265 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 47 |
| Potassium Chloride | Potassium Chloride | 230 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 225 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 63 |
| Allopurinol | Allopurinol | 205 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 39 |
| Ozempic | Semaglutide | 200 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 37 |
| Trazodone Hcl | Trazodone Hcl | 183 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 180 | 49 |
| Furosemide | Furosemide | 178 | 45 |
| Valsartan | Valsartan | 174 | 44 |
| Sertraline Hcl | Sertraline Hcl | 171 | 40 |
| Meloxicam | Meloxicam | 170 | 52 |
| Omeprazole | Omeprazole | 165 | 42 |
| Doxazosin Mesylate | Doxazosin Mesylate | 158 | 37 |
| Buspirone Hcl | Buspirone Hcl | 152 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 26 |
| Montelukast Sodium | Montelukast Sodium | 145 | 37 |
| Glipizide Er | Glipizide | 140 | 29 |
| Famotidine | Famotidine | 139 | 36 |
| Alprazolam | Alprazolam | 138 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 49 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 128 | 97 |
| Glimepiride | Glimepiride | 127 | 32 |
| Lorazepam | Lorazepam | 127 | 18 |
| Clonidine Hcl | Clonidine Hcl | 126 | 27 |
| Clonazepam | Clonazepam | 123 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 122 | 42 |
| Irbesartan | Irbesartan | 120 | 18 |
| Eliquis | Apixaban | 119 | 22 |
| Carvedilol | Carvedilol | 117 | 35 |
| Donepezil Hcl | Donepezil Hcl | 107 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 80 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 22 |
| Nifedipine Er | Nifedipine | 87 | 19 |
| Glipizide | Glipizide | 86 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 81 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 19 |
| Azelastine Hcl | Azelastine Hcl | 73 | 47 |
| Azithromycin | Azithromycin | 72 | 60 |
| Meclizine Hcl | Meclizine Hcl | 67 | 26 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 62 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 16 |
| Simvastatin | Simvastatin | 58 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 17 |
| Jardiance | Empagliflozin | 56 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 55 | suppressed |
| Sucralfate | Sucralfate | 54 | 16 |
| Metformin Hcl Er | Metformin Hcl | 53 | 17 |
| Ondansetron Odt | Ondansetron | 50 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 28 |
| Myrbetriq | Mirabegron | 48 | 14 |
| Cephalexin | Cephalexin | 47 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 11 |
| Finasteride | Finasteride | 44 | 12 |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Topiramate | Topiramate | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 18 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Colchicine | Colchicine | 34 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 13 |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 23 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Nexium | Esomeprazole Magnesium | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 23 |
| Diazepam | Diazepam | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 12 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Humalog | Insulin Lispro | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,104.35 · 51 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ECC Solutions, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE, Fluad, Flucelvax, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, SAPIEN 3 Ultra RESILIA, SHINGRIX, TRELEGY ELLIPTA, Tymlos, UBRELVY, VERQUVO, VRAYLAR, VYNDAMAX, Veozah, Wegovy, Xelstrym, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error